BR112018069487A2 - agente antituberculose - Google Patents

agente antituberculose

Info

Publication number
BR112018069487A2
BR112018069487A2 BR112018069487-8A BR112018069487A BR112018069487A2 BR 112018069487 A2 BR112018069487 A2 BR 112018069487A2 BR 112018069487 A BR112018069487 A BR 112018069487A BR 112018069487 A2 BR112018069487 A2 BR 112018069487A2
Authority
BR
Brazil
Prior art keywords
dimethylphenoxy
pyrimidin
piperidin
dione
methyl
Prior art date
Application number
BR112018069487-8A
Other languages
English (en)
Other versions
BR112018069487B1 (pt
Inventor
Ballell Pages Lluis
Barros Aguirre David
H. Bates Robert
Castro Pichel Julia
Esquivias Provencio Jorge
Pethe Kevin
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Development Limited filed Critical Glaxosmithkline Intellectual Property Development Limited
Publication of BR112018069487A2 publication Critical patent/BR112018069487A2/pt
Publication of BR112018069487B1 publication Critical patent/BR112018069487B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se ao uso na terapia de 6-((4-(2,3-dimetilfenóxi) piperidin-1-il) metil) pirimidina-2,4(1h, 3h)-diona ou um sal farmaceuticamente aceitável do mesmo, incluindo o uso como um antimicobacteriano, por exemplo, no tratamento da tuberculose; composições contendo 6-((4-(2,3-dimetilfenóxi) piperidin-1-il) metil) pirimidina-2,4(1h, 3h)-diona; combinações compreendendo 6-((4-(2,3- dimetilfenóxi) piperidin-1-il)metil) pirimidina-2,4(1h, 3h)-diona ou um sal farmaceuticamente aceitável do mesmo e sais de 6-((4-(2,3-dimetilfenóxi) piperidin-1-il) metil) pirimidina-2,4 (1h, 3h)-diona.
BR112018069487-8A 2016-03-22 2017-03-20 Usos terapêuticos de 6-((4-(2,3-dimetilfenóxi)piperidin-1- il)metil) pirimidina-2,4(1h,3h)-diona ou de um sal farmaceuticamente aceitável da mesma, combinação e composição farmacêutica que compreendem a mesma BR112018069487B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382124.2 2016-03-22
EP16382124 2016-03-22
PCT/EP2017/056565 WO2017162591A1 (en) 2016-03-22 2017-03-20 Antituberculosis agent

Publications (2)

Publication Number Publication Date
BR112018069487A2 true BR112018069487A2 (pt) 2019-02-12
BR112018069487B1 BR112018069487B1 (pt) 2024-04-02

Family

ID=

Also Published As

Publication number Publication date
RS61103B1 (sr) 2020-12-31
HUE051349T2 (hu) 2021-03-01
AR107935A1 (es) 2018-06-28
JP2019512524A (ja) 2019-05-16
CA3018611A1 (en) 2017-09-28
US20190091224A1 (en) 2019-03-28
ZA201806012B (en) 2020-02-26
TW201808295A (zh) 2018-03-16
LT3432887T (lt) 2020-12-10
RU2018136747A (ru) 2020-04-22
US10624893B2 (en) 2020-04-21
DK3432887T3 (da) 2020-11-09
CA3018611C (en) 2024-02-27
KR20180122006A (ko) 2018-11-09
JP6961608B2 (ja) 2021-11-05
RU2756208C2 (ru) 2021-09-28
AU2017237380B2 (en) 2019-12-19
SI3432887T1 (sl) 2020-12-31
CY1123527T1 (el) 2022-03-24
ES2833929T3 (es) 2021-06-16
UY37161A (es) 2017-09-29
KR102479358B1 (ko) 2022-12-19
PL3432887T3 (pl) 2021-05-17
PT3432887T (pt) 2020-12-04
HRP20201861T1 (hr) 2021-01-08
EP3432887A1 (en) 2019-01-30
AU2017237380A1 (en) 2018-09-27
CN108883114A (zh) 2018-11-23
RU2018136747A3 (pt) 2020-05-15
WO2017162591A1 (en) 2017-09-28
EP3432887B1 (en) 2020-09-02
CN108883114B (zh) 2021-08-24

Similar Documents

Publication Publication Date Title
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
PH12018500642A1 (en) Anti-garp antibody
MX2019007587A (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
PH12015502780A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
NZ733174A (en) Quinazoline derivatives used to treat hiv
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112018015718A2 (pt) utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
BR112016026545A8 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
CY1123527T1 (el) Αντιφυματικος παραγοντας
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112015023013A2 (pt) inibidores de quinase cdk9
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
PH12015501555A1 (en) Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
PH12018502139A1 (en) Phosphaplatin liquid formulations
SV2017005527A (es) Agente terapéutico para disfunción del lóbulo frontal
TW201613926A (en) Inhibitors of bruton's tyrosine kinase

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/03/2017, OBSERVADAS AS CONDICOES LEGAIS